Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN) (EPISAT)
A Pharmacoepidemiological Study on the Risk of Bleeding in New Users of Low-dose Aspirin (ASA) in The Health Improvement Network (THIN), UK
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Multiple Locations, United Kingdom
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 40-84 years
- Enrolled with the Primary Care Physician (PCP) for at least 2 years,
- To have a history of computerized prescriptions for at least 1 year prior
- To have at least one encounter/visit recorded in the last three years
Exclusion Criteria:
- To be exposed to low dose ASA before entering in the study
- Having a diagnosis of cancer before entering in the study
- Having a diagnosis of alcohol abuse before entering in the study
- Having a diagnosis of coagulopathies before entering in the study
- Having a diagnosis of esophageal varices before entering in the study
- Having a diagnosis of chronic liver disease before entering in the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Acetylsalicylic Acid
New users of low-dose Acetylsalicylic Acid (ASA)
|
Low-dose ASA for secondary prevention of cardiovascular events
|
|
Other medications
Users of other medications such as clopidogrel, oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs)
|
Secondary prevention of cardiovascular events
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Intracranial bleeding among new users of low-dose Acetylsalicylic acid (ASA).
Time Frame: Up to 13 years
|
Up to 13 years
|
|
|
Incidence of Upper gastrointestinal bleeding among new users of low-dose ASA.
Time Frame: Up to 13 years
|
Up to 13 years
|
|
|
Incidence of Lower gastrointestinal bleeding among new users of low-dose ASA
Time Frame: Up to 13 years
|
Up to 13 years
|
|
|
Time to Intracranial bleeding among new users of low-dose ASA
Time Frame: Up to 13 years
|
Up to 13 years
|
|
|
Time to Upper gastrointestinal bleeding among new users of low-dose ASA
Time Frame: Up to 13 years
|
Up to 13 years
|
|
|
Time to Lower gastrointestinal bleeding among new users of low-dose ASA
Time Frame: Up to 13 years
|
Up to 13 years
|
|
|
Relative risk of Intracranial bleeding among new users of low dose ASA
Time Frame: Up to 13 years
|
Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.
|
Up to 13 years
|
|
Relative risk of Upper gastrointestinal bleeding among new users of low-dose ASA
Time Frame: Up to 13 years
|
Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.
|
Up to 13 years
|
|
Relative risk of Lower gastrointestinal bleeding among new users of low-dose ASA
Time Frame: Up to 13 years
|
Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.
|
Up to 13 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relative risk of Intracranial bleeding associated with use of other medications.
Time Frame: Up to 13 years
|
Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.To estimate relative risk in users of other medications such as clopidogrel,oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs), independently from use of low-dose ASA and concomitantly
|
Up to 13 years
|
|
Relative risk of Upper gastrointestinal bleeding associated with use of other medications
Time Frame: Up to 13 years
|
Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.To estimate relative risk in users of other medications such as clopidogrel,oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs), independently from use of low-dose ASA and concomitantly
|
Up to 13 years
|
|
Relative risk of Lower gastrointestinal bleeding associated with use of other medications.
Time Frame: Up to 13 years
|
Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.To estimate relative risk in users of other medications such as clopidogrel,oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs), independently from use of low-dose ASA and concomitantly
|
Up to 13 years
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Cea Soriano L, Gaist D, Soriano-Gabarro M, Bromley S, Garcia Rodriguez LA. Low-dose aspirin and risk of intracranial bleeds: An observational study in UK general practice. Neurology. 2017 Nov 28;89(22):2280-2287. doi: 10.1212/WNL.0000000000004694. Epub 2017 Nov 1.
- Cea Soriano L, Gaist D, Soriano-Gabarro M, Garcia Rodriguez LA. Incidence of intracranial bleeds in new users of low-dose aspirin: a cohort study using The Health Improvement Network. J Thromb Haemost. 2017 Jun;15(6):1055-1064. doi: 10.1111/jth.13686. Epub 2017 May 2.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Heart Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Aspirin
- Clopidogrel
- Anticoagulants
Other Study ID Numbers
Other Study ID Numbers
- 18116
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.